Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.10 Insider Own6.35% Shs Outstand6.07M Perf Week-22.53%
Market Cap17.64M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.69M Perf Month-39.47%
Income-0.31M PEG- EPS next Q- Inst Own0.01% Short Float0.13% Perf Quarter-31.80%
Sales0.00M P/S- EPS this Y- Inst Trans-6.45% Short Ratio2.59 Perf Half Y-57.38%
Book/sh8.08 P/B0.36 EPS next Y- ROA-0.50% Short Interest0.01M Perf Year-51.58%
Cash/sh6.82 P/C0.43 EPS next 5Y- ROE-1.22% 52W Range2.70 - 13.00 Perf YTD-34.57%
Dividend Est.- P/FCF- EPS past 5Y70.34% ROI-0.87% 52W High-77.65% Beta2.36
Dividend TTM- Quick Ratio3.65 Sales past 5Y0.00% Gross Margin- 52W Low7.60% ATR (14)0.34
Dividend Ex-Date- Current Ratio3.65 EPS Y/Y TTM99.59% Oper. Margin0.00% RSI (14)27.65 Volatility8.08% 6.14%
Employees49 Debt/Eq0.58 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.39
Option/ShortNo / Yes LT Debt/Eq0.43 EPS Q/Q102.69% Payout- Rel Volume0.49 Prev Close2.83
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume2.89K Price2.91
SMA20-30.37% SMA50-35.58% SMA200-52.60% Trades Volume1,415 Change2.66%
Feb-20-24 04:05PM
Feb-06-24 04:05PM
Jan-18-24 04:05PM
Jan-03-24 04:05PM
Dec-06-23 04:05PM
04:05PM Loading…
Nov-14-23 04:05PM
Nov-07-23 12:00PM
Oct-24-23 04:05PM
Oct-23-23 04:05PM
Jun-28-23 04:05PM
Jun-27-23 12:00PM
Jun-26-23 04:05PM
Jun-23-23 04:30PM
Jun-20-23 04:05PM
02:00PM Loading…
Jun-14-23 02:00PM
Jun-13-23 12:00PM
Jun-12-23 01:00AM
Jun-05-23 02:00AM
May-24-23 04:05PM
May-23-23 04:05PM
May-16-23 12:00PM
May-15-23 04:45PM
May-12-23 12:00PM
May-09-23 02:00AM
Apr-17-23 04:05PM
Apr-12-23 12:00PM
Mar-22-23 05:05PM
Mar-06-23 12:00PM
Feb-15-23 04:30PM
12:00PM Loading…
Feb-09-23 12:00PM
Jan-09-23 12:00PM
Dec-06-22 12:00PM
Nov-21-22 04:05PM
Oct-13-22 04:05PM
Oct-05-22 12:00PM
Oct-04-22 12:00PM
Sep-12-22 04:05PM
Sep-06-22 04:30PM
Aug-26-22 01:21PM
Aug-25-22 06:35AM
Aug-24-22 04:05PM
Jul-07-22 12:00PM
Jun-24-22 04:05PM
Jun-03-22 12:00PM
May-24-22 04:05PM
May-17-22 04:05PM
May-13-22 12:00PM
May-12-22 04:05PM
Apr-28-22 04:05PM
Apr-25-22 02:00AM
Apr-06-22 04:05PM
Apr-04-22 01:30AM
Mar-28-22 04:05PM
Mar-11-22 05:18PM
Mar-04-22 12:00PM
Feb-09-22 12:53PM
Feb-08-22 04:05PM
Jan-10-22 12:00PM
Jan-03-22 04:05PM
Dec-14-21 01:30AM
Dec-13-21 04:05PM
Dec-10-21 12:00PM
Dec-01-21 09:22AM
Nov-29-21 04:05PM
Nov-15-21 04:05PM
Nov-10-21 01:30AM
Nov-09-21 02:00AM
Nov-05-21 01:21PM
Oct-25-21 12:11PM
Oct-07-21 12:00PM
Oct-04-21 04:05PM
Sep-28-21 04:05PM
Sep-22-21 12:30PM
Sep-20-21 04:05PM
Sep-15-21 04:05PM
Sep-06-21 04:05PM
Sep-03-21 12:00PM
Aug-30-21 04:05PM
Aug-24-21 04:30PM
Aug-05-21 12:00PM
Jul-30-21 08:50AM
Jul-29-21 04:05PM
Jul-27-21 01:30AM
Jul-21-21 04:05PM
Jul-06-21 12:00PM
Jun-25-21 04:30PM
Jun-07-21 12:00PM
May-26-21 04:30PM
May-25-21 04:00PM
May-07-21 12:00PM
May-04-21 04:30PM
Apr-29-21 02:30AM
PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.